

Why Open Access?




Journal Oxidative Medicine and Cellular Longevity




We are hiring: Insight Analyst

Career

We are looking for an Insight Analyst to join our growing team in London.

 G. Currie

 05 May 2022

4 ways we have improved the submission platform for our authors

Authors | Editors | Peer Review

These four improvements in Phenom will help deliver a seamless publishing...

Advanced Gut & Microbiome Research




First partnership journal with a Chinese partner


Publishing partnerships

Advanced Gut & Microbiome Research will publish with Hindawi under a new collaborative publishing agreement.

 P. Li

 12 Apr 2022


 C. Farrell


 24 Mar 2022

We are hiring: Partner Success Manager – Project Management

Career

We are looking for a Partner Success Manager – Project Management to join...

 G. Currie

 09 Mar 2022

Our mission

By placing the research community **at the heart of everything we do**, we strive for a future where researchers are motivated to work together, **empowered** with the tools and services they need to do so, and **freed** from any barriers that stand in their way. We aim to **maximize the impact** of scientific research through **openness** and global **collaboration** as we truly believe that science works best when **research is open**.

For publishers



To assist publishers and societies in embracing the advantages offered by an open access publishing model, we have created Phenom - a simple, intuitive, cost-effective publishing solution that supports all workflows; from submission and peer review through to production and publication.

Partner with us



For authors



With the researcher at the heart of the publishing experience, we have created a diverse portfolio of peer-reviewed, open access journals across a wide range of scientific and medical disciplines. Choose the journal that fits your niche.

Publish with us



Editors

This section offers guidance and resources to assist our Editors in their roles.

[Browse our journals](#) for information about specific journal Editorial Boards, editorial models, and editorial processes.

The Editor Community

As an editor, you have exclusive access to the Editor Community, an online platform providing you with valuable features that will enhance your experience with Hindawi. Log in today and receive full access to the following:

- Editor Support – explore our extensive collection of editor resources and how-to guides to support you with all aspects of your role.
- Community Live Feed - stay informed with weekly updates covering editor related news and other important announcements.
- Events and conferences - share news of your upcoming conference plans with fellow editors.
- Connect with colleagues - learn more about editors across all our journals.

[Enter the Editor Community Site](#)

Resources for Academic Editors

The following resources are available for your reference without logging in, and for the interest of authors and prospective new Editors.

[Editors' roles and responsibilities](#)

[Handling a manuscript](#)

[Interpreting similarity reports](#)

[Assessing Special Issues](#)

Become an Editor

Are you interested in being an editor on a Hindawi journal? Or are you a current editor and wish to suggest a colleague to join your Editorial Board? Learn more about the benefits of becoming an editor on our [Editor Community](#), or fill in the application form. We'd love to hear from you.

[Editor application and nomination form](#)

Becoming a Special Issue Guest Editor

If you would like to run your own Special Issue, the following resources will guide you through the process, from assembling your Guest Editor team and writing your proposal, through to advertising your Call for Papers and managing submissions, to celebrating your published Issue.

[Find out more on Special Issues](#)

Reviewers

Applications to review

We appreciate applications to join our community of peer reviewers.

Please apply below if you wish to become a reviewer for specific Hindawi journals.

You may also be contacted with requests to review for other journals in your subject area.

Please note that completion of this form does not guarantee that you will be contacted to review. Our Academic Editors select reviewers on a manuscript-by-manuscript basis. In each case, the most relevant scientists will be invited.

[Become a reviewer for Hindawi](#)

How to peer review for Hindawi

The reviewer report should comprehensively critique the submission and consist of much more than a few brief sentences. Hindawi does not require a specific structure for reports, however, a suggested format is:

- Summary
- Major issues
- Minor issues

We encourage reviewers to help authors improve their manuscript. The report should give constructive analysis to authors, particularly where revisions are recommended. Where reviewers do not wish authors to see certain comments, these can be added to the confidential comments to the Academic Editor.

While expectations vary by discipline, some core aspects that should be critiqued by reviewers may include:

- Are the research questions valid?
- Is the sample size sufficient?
- Is there necessary ethical approval and/or consent and was the research ethical?
- Are the methods and study design appropriate for answering the research question?
- Do the experiments have appropriate controls?
- Is the reporting of the methods, including any equipment and materials, sufficiently detailed that the research might be reproduced?
- Are any statistical tests used appropriate and correctly reported?
- Are the figures and tables clear and do they accurately represent the results?
- Has previous research by the authors and others been discussed and have those results been compared to the current results?
- Are there any inappropriate citations, for example, not supporting the claim being made or too many citations to the authors' own articles?
- Do the results support the conclusions?
- Are limitations of the research acknowledged?
- Is the abstract an accurate summary of the research and results, without spin?
- Is the language clear and understandable?

To help authors receive timely reviews, reviewer reports should be submitted via the manuscript tracking system on or before the agreed deadline. Reviewers should contact Hindawi if they are unable to meet the deadline so an alternative date can be arranged.

We encourage reviewers to focus their reports on objectively critiquing the scientific aspects of the submission, including the soundness of the methodology and whether the conclusions can be supported by the results. At the end of their review, we ask reviewers to recommend one of the following actions:

- Publish Unaltered
- Consider after Minor Changes
- Consider after Major Changes
- Reject

However, it is important to note that the overall decision will be made by the Academic Editor.

Page Sections

- [CONSORT](#) for randomized controlled trials
- [TREND](#) for non-randomized trials
- [PRISMA](#) for systematic review and meta-analyses
- [CARE](#) for case reports
- [STROBE](#) for observational studies
- [STREGA](#) for genetic association studies
- [SRQR](#) for qualitative studies
- [STARD](#) for diagnostic accuracy studies
- [ARRIVE](#) for animal experiments

Publication ethics

Hindawi is a member of the Committee on Publication Ethics (COPE). Read the [COPE Ethical Guidelines for Peer Reviewers](#) for information on best practice in peer review.

Reviewers should raise any concerns about publication ethics to the [Research Integrity team](#).

[See Hindawi's ethics policy](#)

Confidentiality

Manuscripts under peer review should be strictly confidential. Reviewers must not share manuscripts or discuss their content with anyone outside the peer review process.

Reviewers may, on request, consult with colleagues from their research group trusting that the confidentiality of the manuscript is maintained. Reviewers should first contact Hindawi or the Academic Editor handling the manuscript and note the name of the colleague(s) in the 'Comments to the editor' section of their report.

Reviewers will be anonymous to the authors unless they choose to disclose their identity by signing the review report.

Conflicts of interest

Reviewers should decline to review a submission when they:

- Have a recent publication or current submission with any author
- Share or have recently shared an affiliation with any author
- Collaborate or have recently collaborated with any author
- Have a close personal connection to any author
- Have a financial interest in the subject of the work
- Feel unable to be objective

Reviewers must declare any remaining interests in the 'Confidential' section of the review form, which will be considered by the editor.

Reviewers must declare if they have previously discussed the manuscript with the authors.

Reviewers are encouraged to comment on authors' declared conflicts of interest. If there are concerns that authors have not fully disclosed financial, institutional, commercial, personal, ideological, or academic interests, this should be raised in the reviewer report.

Table of Contents

2022



Oxidative Medicine and Cellular Longevity - **Special Issue** - Volume 2022 - Article ID 8123120 - Research Article

N-((1-(4-Fluorophenyl)-1H-1,2,3-triazol-4-yl)methyl)-2-methylene-3-oxo-olean-12-en-28-amide Induces Apoptosis in Human Breast Cancer Cells by Stimulating Oxidative Stress and Inhibiting the Notch-Akt Signaling Pathway

Xiaorui Li | Shisheng Wang | ... | Tao Sun

27 Apr 2022

[Download PDF](#)


Oxidative Medicine and Cellular Longevity - **Special Issue** - Volume 2022 - Article ID 9469143 - Research Article

Tumor Necrosis Factor- α -Induced Protein 8-Like 2 Ameliorates Cardiac Hypertrophy by Targeting TLR4 in Macrophages

Rui Yao | Lingyao Kong | ... | Yapeng Li

26 Apr 2022

[Download PDF](#)


Oxidative Medicine and Cellular Longevity - **Special Issue** - Volume 2022 - Article ID 5918954 - Research Article

Magnesium Hydride Ameliorates Endotoxin-Induced Acute Respiratory Distress Syndrome by Inhibiting Inflammation, Oxidative Stress, and Cell Apoptosis

Xuan Shi | Lina Zhu | ... | Xin Lv

26 Apr 2022

[Download PDF](#)


Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 9059371 - Research Article

Yttrium Oxide Nanoparticles Moderate the Abnormal Cognitive Behaviors in Male Mice Induced by Silver Nanoparticles

Gasem Mohammad Abu-Taweel | Mohsen Ghaleb Al-Mutary | Hani Manssor Albetran

26 Apr 2022

[Download PDF](#)


Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 8244497 - Research Article

Interleukin 10 Attenuates Angiotensin II-Induced Aortic Remodelling by Inhibiting Oxidative Stress-Induced Activation of the Vascular p38 and NF- κ B Pathways

Ming Qiu | Huanyu Shu | ... | Xiangqing Kong

26 Apr 2022

[Download PDF](#)


+ Journal Menu

Oxidative Medicine and Cellular Longevity - **Special Issue** - Volume 2022 - Article ID 2550857 - Research Article**DDAH1/ADMA Regulates Adiponectin Resistance in Cerebral Ischemia via the ROS/FOXO1/APR1 Pathway**

Yichen Zhao | Minjie Zhang | ... | Yanxin Zhao

25 Apr 2022

[Download PDF](#)

Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 3081397 - Research Article

Antioxidative Stress and Antiapoptosis Effect of Chitosan Nanoparticles to Protect Cardiac Cell Damage on Streptozotocin-Induced Diabetic Rat

Giftania Wardani | Jusak Nugraha | ... | Sri Agus Sudjarwo

25 Apr 2022

[Download PDF](#)

Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 2122856 - Review Article

Plin5, a New Target in Diabetic Cardiomyopathy

Xiangning Cui | Jingwu Wang | ... | Yan Wang

25 Apr 2022

[Download PDF](#)

Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 5759626 - Research Article

COX-2/sEH Dual Inhibitor PTUPB Attenuates Epithelial-Mesenchymal Transformation of Alveolar Epithelial Cells via Nrf2-Mediated Inhibition of TGF- β 1/Smad Signaling

Chen-Yu Zhang | Xin-Xin Guan | ... | Yong Zhou

25 Apr 2022

[Download PDF](#)

Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 8336070 - Research Article

Simvastatin Inhibits NLRP3 Inflammasome Activation and Ameliorates Lung Injury in Hyperoxia-Induced Bronchopulmonary Dysplasia via the KLF2-Mediated Mechanism

Xinye Wang | Ran Huo | ... | Shangqin Chen

25 Apr 2022

[Download PDF](#)

Oxidative Medicine and Cellular Longevity - Volume 2022 - Article ID 5595781 - Research Article

Reversal of NADPH Oxidase-Dependent Early Oxidative and Inflammatory Responses in Chronic Obstructive Pulmonary Disease by Puerarin

Pan Zhang | Yixuan Zhang | ... | Hua Cai

25 Apr 2022

[Download PDF](#)

Oxidative Medicine and Cellular Longevity - **Special Issue** - Volume 2022 - Article ID 4943965 - Research Article

Evaluation of Antiarthritic and Antinociceptive Effects of Cedrol in a Rat Model of Arthritis

Fatemeh Forouzanfar | Ali Mohammad Pourbagher-Shahri | Hamed Ghazavi

25 Apr 2022

[Download PDF](#)



Oxidative Medicine and Cellular Longevity - **Special Issue** - Volume 2022 - Article ID 9865606 - Research Article

Assessing the Role of Nrf2/GPX4-Mediated Oxidative Stress in Arsenic-Induced Liver Damage and the Potential Application Value of Rosa roxburghii Tratt [Rosaceae]

Yuyan Xu | Qibing Zeng | ... | Aihua Zhang

25 Apr 2022

[Download PDF](#)



[First](#)

[←](#) [8](#) | [9](#) | **[10](#)** | [11](#) [→](#)

[Last](#)



[Author guidelines](#)



[Editorial board](#)



[Databases and indexing](#)



[Sign up for content alerts](#)

[Sign up](#)

Follow us:



[About us](#)

[Contact us](#)

[Careers](#)

[Blog](#)

[Journals](#)

[Article Processing Charges](#)

[Print editions](#)

[Authors](#)

[Editors](#)

[Reviewers](#)

Research Article

Antioxidative Stress and Antiapoptosis Effect of Chitosan Nanoparticles to Protect Cardiac Cell Damage on Streptozotocin-Induced Diabetic Rat

Giftania Wardani ^{1,2}, Jusak Nugraha ³, Mohd. Rais Mustafa ⁴, Rochmah Kurnijasanti,⁵ and Sri Agus Sudjarwo ⁵

¹Doctoral Program of Medical Science, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

²Study Program of Pharmacy, Hang Tuah University, Surabaya, Indonesia

³Department of Clinical Pathology, Dr Soetomo Hospital, Universitas Airlangga, Surabaya, Indonesia

⁴Department of Pharmacology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

⁵Department of Pharmacology, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, Indonesia

Correspondence should be addressed to Sri Agus Sudjarwo; ags158@yahoo.com

Received 26 January 2022; Revised 22 March 2022; Accepted 1 April 2022; Published 25 April 2022

Academic Editor: Massimo Lucarini

Copyright © 2022 Giftania Wardani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The antioxidant can inhibit oxidative stress and apoptosis, which has a role in an important mechanism on diabetic-induced cardiac cell damage. The research goal was to prove the antioxidative stress and antiapoptosis effect of chitosan nanoparticles as a cardioprotector in streptozotocin-induced diabetic rats. Scanning electron microscope (SEM) and dynamic light scattering (DLS) characterize the chitosan nanoparticles. This research is a laboratory experiment which consists of the control group (rats were given distilled water), the streptozotocin group (rats were injected streptozotocin at dose of 55 mg/kg BW i.p), and the chitosan nanoparticle group (rats were given streptozotocin at dose 55 mg/kg BW i.p, and then given chitosan nanoparticles at dose 75 mg/kg BW, 150 mg/kg BW, and 300 mg/kg BW peroral). Creatine kinase-myoglobin (CK-MB) and lactate dehydrogenase (LDH) were measured from the blood sample. Malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPx) from cardiac tissue were examined by ELISA; nuclear factor erythroid 2-related factor 2 (Nrf2) was evaluated by western blotting; B-cell lymphoma 2 (Bcl-2) and Caspase-3 expression were investigated by immunohistochemical staining and also were evaluated histological preparation by hematoxylin & eosin (H&E) staining. The chitosan nanoparticles have a rough surface and an irregular shape. Its size is $247.3 \pm 38.1 \mu\text{m}$. Streptozotocin injection significantly increased the levels of CK-MB, LDH, MDA, and expression of caspase-3. In contrast, the levels of SOD, GPx, Nrf2, and expression of Bcl-2 decreased as compared with the control group ($p < 0.05$). This is accompanied by the loss of normal cardiac cell structure and necrosis. The administration of chitosan nanoparticles significantly reduced levels of CK-MB, LDH, MDA, and expression of Caspase-3. However, the levels of SOD, GPx, Nrf2, and expression of Bcl-2 increased as compared with the streptozotocin group ($p < 0.05$). And also, chitosan nanoparticles inhibited cell necrosis in diabetic rats. This study suggests that the administration of chitosan nanoparticles can protect cardiac cell damage in diabetic rats through antioxidative stress by decreasing ROS and increasing Nrf2 expression, level of SOD, and GPx and through antiapoptosis by increasing expression of Bcl-2 and decreasing expression of Caspase-3.

1. Introduction

Diabetes mellitus is a metabolic disease characterized by hyperglycemia due to insulin deficiency or resistance to insulin action or both, which can be accompanied by

long-term microvascular and macrovascular complications, leading to morbidity and mortality [1, 2].

Many studies report that diabetic complications that result in cardiac cell damage are associated with oxidative stress and apoptosis. The molecular mechanism of diabetes

complications seems to be multifactorial, with various consequences for cellular function. It has been reported that apoptosis occurs after oxidative stress and is enhanced during diabetes complications-induced cardiac cell damage [3–5]. Hyperglycemia in diabetes can increase advanced glycosylated end products (AGEs), and increased Protein Kinase C activity results in an increase in the production of superoxide in the mitochondria. This effect causes an increase in oxidative stress due to the excessive production of free radicals [6]. Prolonged hyperglycemia can lead to oxidative stress due to the overproduction of reactive oxygen species (ROS) such as O_2^- , OH^- , and H_2O_2 , which counteract cellular redox balance and cause decreased antioxidants such as SOD, GPx, and Cat. Oxidative stress causes significant damage to several cellular biomolecules, including proteins, lipids, and DNA [7–9]. The resulting dysregulated expression of many genes and proteins leads to cell apoptosis and necrosis, contributing to the progression of diabetes complications such as retinopathy, neuropathy, nephropathy, and cardiomyopathy [3, 10]. Preclinical and human research has found a relation between hyperglycemia, ROS overproduction, and the occurrence of myocyte apoptosis [11, 12].

Apoptosis has an essential role in the pathogenesis of cardiac cell damage due to complications of diabetes. Caspase-3 is one of the main executors of apoptosis, and increased caspase-3 activity indicates the presence of cell apoptosis. Bax and Bcl-2 are apoptotic and antiapoptotic proteins, with the ratio of these two proteins determining the occurrence of cell apoptosis. Bcl-2 is an antiapoptotic regulator. Bcl-2 inhibits the release of cytochrome c and the formation of the apoptosome with Apaf1, which leads to the inhibition of caspase 9 and subsequently of caspase-3 [13, 14]. New studies show that Bcl2 decreases and caspase-3 increases cardiac cell damage in streptozotocin-induced diabetic rats. Excessive ROS formation accelerates the process of apoptosis by inhibiting Bcl-2 expression and increasing caspase-3 activity, which shows that a relationship exists between oxidative stress and apoptosis [15, 16].

In addition, induction with streptozotocin in a diabetic rat model can enhance ROS and lower antioxidant enzyme effects [17, 18]. A previous study revealed that Nrf2 is a primary antioxidant regulator, and streptozotocin-induced decreased expression of Nrf2 is associated with decreased antioxidant linkage, as demonstrated by various investigators [15, 19]. Furthermore, ROS will oxidize cell membrane lipid that produces malondialdehyde (MDA) and may be used as a marker of tissue damage. The increase in MDA level indicates enhanced lipid peroxidation, causing cell necrosis or apoptosis in cardiac cell damage in diabetics. CK-MB and LDH levels in serum are used as marker enzymes of cardiac cell damage. This enzyme passes through the injured tissue and is the most effective sign of cardiomyopathy [3, 16, 20].

Several studies have shown that antioxidants can both prevent and cure cell injury induced by an increase in free radicals in the body. Exogenous antioxidants like natural products have been used to avoid free radical production in streptozotocin-induced cardiac cell damage in diabetic rats [16, 21]. The crude product is used as an alternative product

to antioxidants because of its cheap cost and few side effects. One of the antioxidants found in natural products is chitosan, which is used in this research to inhibit oxidative stress and apoptosis in the cardiac cell damage of diabetic rats. Researchers have extensively reported chitosan for its antioxidant activity and are utilized for studies in both in vivo and in vitro [22, 23]. This indicates that chitosan regulates the activity of antioxidant enzymes and reduces lipid peroxidation. Recently, chitosan has attracted much attention due to various biological activities associated with its antioxidant activity. Chitosan also has pharmacological properties such as hepatoprotective, nephroprotective, antiulcer, anticancer, immunostimulant, and antioxidant [24, 25]. It has been reported that chitosan is broadly used in pharmaceutical, industrial, and medical applications.

Recently, the production of natural medicine nanoparticles has played an important role in nanotechnology. The natural medicine nanoparticle has been given attention for prevention and therapeutic disease in both animals and humans. Compared to pure natural medicine, the nanoparticle-based natural treatment improved drug stability, delivery system, effectiveness, and penetration ability [26, 27]. Therefore, it is necessary to make chitosan preparations in the form of nanoparticles so the absorption, distribution, activity, and effectiveness of chitosan are improved as an antioxidant and antiapoptotic and can protect heart cell damage in diabetics.

2. Materials and Methods

2.1. Preparation of Chitosan Nanoparticles by Ball Milling Methodology. The chitosan powder (Sigma-Aldrich, Co, USA) was milled using a high-energy ball equipped with an insulating sheath and a cooling machine. The weight ratio of chitosan powder to the ball (1 : 20) in stainless steel bottles (50 ml). The container is filled to about a third of its capacity. During milling, the flask was rotated at a constant milling speed of 500 rpm for 5 h. The direction of rotation of the ball mill is changed every 30 minutes. The ball milling process is conducted at a temperature of 27°C, and the temperature is maintained with the air conditioning system to prevent overheating.

Scanning electron microscopy was used to evaluate the characteristics of the surface morphology, including the shape, size, and topography of the chitosan nanoparticles as follows: 0.1 g of chitosan nanoparticle powder was suspended in 10 ml of ethanol. Then, the suspension was sonicated for 20 minutes and dripped onto carbon tape, which stuck and dried. Furthermore, it is coated with gold and placed on a ready SEM tool so that the results of the character and size of the chitosan nanoparticles can be obtained.

And also carried out the identification particle size of chitosan nanoparticles by dynamic light scattering (DLS) (Horiba LA, Japan) as follows: to another particle, the nanoparticles must be filtered. Then, put chitosan nanoparticles in a clean cuvette until 2/3 of the cuvette is filled. After that, the cuvette containing the chitosan nanoparticle solution is inserted into the tool and closed with a sensor. Before measuring, the temperature is first set at 25°C by pressing the

“Temp. Panel” menu. Standard starts counting by pressing the “Auto1” menu. Then, the tool will automatically measure the amount the particle size has been measured six times.

2.2. Ethical Approval. This research has been conducted through an ethical feasibility test, and all procedure experiments have been agreed upon by the Committee of the Ethical Clearance for Research in Preclinical, Faculty of Medicine, Hang Tuah University, Surabaya, Indonesia.

2.3. The Animal Experimental. In this experiment, we used male Wistar rats weighing about 225-250 g and aged between 2.5 and 3 months. The rat was obtained from Gajah Mada University in Yogyakarta, Indonesia. Rats were placed in a plastic cage in an air-conditioned room with a temperature maintained at 26°C. In addition, the dark and light cycles were alternated for 12 hours. The rat was given free feed, a standard commercial, and drinking water ad libitum.

2.4. A Diabetic Model Rat. The rat fasted overnight and then was injected with streptozotocin (Sigma Aldrich, Co, USA) at a dose of 55 mg/kg BW intraperitoneal (i.p) that was dissolved in citrate buffer (0.1 M; pH 4.5). Three days after the streptozotocin injection, blood samples were taken through the lateral vein of the tail and tested for blood glucose levels by the glucometer (Accu-Check, Roche Diagnostics, Pvt. Ltd.). Rats with a glucose level of >250 mg/dL could be used as experimental animals.

2.5. Experimental Designs. Forty rats were randomized into the control group (rats were given aqua dest), the streptozotocin group (rats were injected at a dose of 55 mg/kg BW i.p), and the chitosan nanoparticle group (rats were injected with streptozotocin at a dose of 55 mg/kg BW, and after 3 days, rats were given chitosan nanoparticles at doses of 75 mg, 150 mg, and 300 mg/kg BW orally once a day for 75 days). After 75 days of treatment, all the rats were anesthetized by intraperitoneal (i.p.) injection of 100 mg/kg ketamine (Ketalar, Pfizer, USA), and all groups were taken blood by intracardial to measure the level of CK-MB and LDH. The heart was collected and fixed in 10% buffered formalin for observation of heart damage in histopathological preparation. We measured the levels of MDA, SOD, and GPx by ELISA, Nrf2 expression by western blotting, expression of Bcl-2, and caspase-3 by immunohistochemical staining.

2.6. Measurement of MDA in Heart Tissue. MDA was measured in the supernatant of homogenized heart tissue using the thiobarbituric acid (TBA) technique, which predicts MDA production. The absorbance coefficient of the MDA-TBA complex was used to assess the level of MDA, which was measured at 532 nm. The Lipid Peroxidation Colorimetric/Fluorometric Assay Kit (Biovision K739-100; Milpitas, CA95035, USA) was used to determine MDA levels. The results were expressed as nanomole MDA per milligram of tissue (nmol/mg tissue).

2.7. Measurement of Antioxidant Enzymes (SOD and GPx) in Heart Tissue. A total of 50 mg of heart tissue was washed with phosphate-buffered saline (PBS) containing 137 mM

NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, and 1.8 mM KH₂PO₄ five times until clean. The sample was pounded with a mortar, then 0.5 ml of sample buffer was added, and it was centrifuged at 10,000 rpm for 10 minutes. The supernatant was taken. Rat SOD ELISA kits (Biovision-K335-100; Milpitas, CA95035, USA) were used to measure the SOD level. Similarly, GPx was also measured with the rat GPx ELISA kit t (Biovision-K762-100; Milpitas, CA95035, USA) according to the manufacturer's protocol. Enter the sample into a standard microplate incubate at 37°C for 90 minutes. Incubate the biotinylated antibody for 60 minutes at 37°C before washing three times with PBS 0.01 M. Incubate the plate at 37°C for 30 minutes with the Avidin-Biotin Complex working solution. Dish with PBS, 0.01 M. Incubates the TMB color developing agent for 30 minutes at 37°C. TMB stop solution and read the OD value on a 450 nm microplate reader. Furthermore, a standard curve is made between the value of OD and concentration so that we get the concentration SOD and GPx levels in pg/ml.

2.8. Immunohistochemical Staining of Bcl-2 and Caspase-3 Expression. Immunohistochemical staining was utilized to observe Bcl-2 and Caspase-3 expression. Heart tissue slices 4 μm were deparaffinized and were added hydrogen peroxide at 37°C for 10 minutes to inhibit endogenous peroxide. Then, 10% normal sheep serum was given in Tris-buffered salt solution at 37°C for 30 minutes and, furthermore, incubated overnight at 4°C with anti-Bcl-2 monoclonal (1:100; Santa Cruz Biotechnology, USA) or anti-rat anti-caspase3 monoclonal (1:100, Santa Cruz Biotechnology, USA) antibodies. After that, they were washed three times with PBS and incubated with a secondary antibody from the Ultra Vision Quanto Detection System HRP DAB (Thermo Fisher Scientific, Waltham, MA, USA) for 30 minutes at room temperature and with 3.3' diaminobenzidine (DAB) color reagent. Immunohistochemical expressions were observed by microscopy and semiquantified by Image-Pro Plus 6.0 software. The integrated optical density (IOD) of each photo was collected. Images were measured by immunoreactive area (IA) in μm² and IOD. The staining intensity (SI) for each image was calculated as SI = IOD/IA and the mean with a standard deviation.

2.9. Western Blotting Analysis of Nrf2 Protein. A total of 50 mg protein from heart tissue was subjected to electrophoresis on 12% SDS-PAGE and transferred to the nitrocellulose membrane. The membrane was blocked in 5% skim milk at room temperature for 30 minutes and then probed with rat anti Nrf2 antibody (Invitrogen, ThermoFisher, Scientific, USA) at 4°C overnight; the membranes were incubated with HRP-conjugated secondary antibody for 1 hour at 37°C. Beta-actin was used for control. Bands were visualized and analyzed by densitometry with the Typhoon FLA 9500 (GE Healthcare, Uppsala, Sweden).

2.10. Measurement of CKMB and LDH. The enzymes CK-MB and LDH, which are linked to heart cell damage, were tested in the serum. The experiments were carried out using

commercially available test kits (Sigma-Aldrich Corp., MO, USA) and following the manufacturer's instructions.

2.11. Histopathological Examination. Rat's heart tissue was collected and fixed in 10% buffered formalin solution, dehydrated in ethanol, and embedded in paraffin. Heart tissue sectioned at 4 μm was stained with hematoxylin and eosin. The photomicrographs of each tissue section were observed using cell imaging software for life science microscopy (Olympus Soft Imaging Solution GmbH, Munster, Germany).

2.12. Statistical Analysis. The data were presented in the form of mean \pm standard deviation. The one-way analysis of variance (ANOVA) is used to analyze the data and will be continued with the LSD test through the application of SPSS 17.0 (SPSS Inc, Chicago, USA).

3. Results

3.1. Characterization of Chitosan Nanoparticles. Chitosan nanoparticle in scanning electron microscopy (SEM) shows a rough surface morphology and an uneven shape (Figure 1).

DLS shows that the chitosan nanoparticles particle size is approximately $247.3 \pm 38.1 \mu\text{m}$ (Figure 2).

3.2. The Effect of Chitosan Nanoparticles on MDA, SOD, and GPx of Diabetic Rat Heart. The results of the ELISA assay demonstrated that the streptozotocin-induced cardiac cell damage significantly increased in the level of MDA and decreased in the level of SOD and GPx as compared with the control group ($p < 0.05$). However, we found that dose-dependent the administration of chitosan nanoparticles and only at dose 300 mg/kg BW significantly reduced the level of MDA and enhanced the level of SOD and GPx as compared with the streptozotocin group ($p < 0.05$) (Table 1).

3.3. The Effect of Chitosan Nanoparticles on Nrf2 Protein Expression of Diabetic Rat Heart. Western blot analysis revealed that Nrf2 protein expression was significantly decreased in heart of the streptozotocin-induced diabetic rat ($p < 0.05$) as compared with the control group (Figure 3). However, dose-dependent administration of chitosan nanoparticles and only at dose 300 mg/kg BW significantly increased Nrf2 protein expression as compared with streptozotocin-induced diabetic rats.

3.4. Effect of Chitosan Nanoparticle on Bcl-2 of Diabetic Rat Heart. To prove that chitosan nanoparticles are involved in apoptosis on streptozotocin-induced diabetic rats, we measured antiapoptosis Bcl-2 expression by immunohistochemical staining. The administration of streptozotocin significantly decrease Bcl-2 expression compared to the control group ($p < 0.05$). However, dose-dependent administration of chitosan nanoparticles could increase the expression of Bcl2 (Figure 4).

3.5. Effect of Chitosan Nanoparticle on Caspase-3 of Diabetic Rat Heart. To prove that chitosan nanoparticles are involved in apoptosis on streptozotocin-induced diabetic rats, we measured executioner Caspase-3 expression by immunohistochemical staining. The administration of streptozotocin

significantly increase Caspase-3 expression compared to the control group ($p < 0.05$). However, dose-dependent administration of chitosan nanoparticles could decrease caspase-3 (Figure 5) ($p < 0.05$).

3.6. The Effect of Nanoparticle Chitosan on the Serum Level of CK-MB and LDH of Diabetic Rat. As a marker of cardiac cell injury, the serum level of CK-MB and LDH was significantly increased in the streptozotocin-induced diabetic rat ($p < 0.05$). Following administration of chitosan nanoparticles only at a dose of 300 mg/kg BW significantly decreased level of the CK-MB and LDH ($p < 0.05$) (Table 2).

3.7. The Effect of Chitosan Nanoparticles on the Structural Change of Diabetic Rat Heart. To evaluate the nephroprotective effect of chitosan nanoparticles, we conducted a histopathological examination of streptozotocin-induced cardiac cell injury in diabetic rats. Light microscope investigation revealed that the control group is the normal structure of the heart. The administration of streptozotocin can cause morphological irregularities, several cardiac cell degeneration, and necrosis (Figure 6). The treatment with chitosan nanoparticles could inhibit cardiac cell necrosis and protect the normal structure of the heart.

4. Discussion

Many researchers have developed an interest in synthesizing nanoparticles to enhance their biological activity, especially those used as antioxidant agents. A natural product of nanotechnology can increase bioavailability, biodistribution, sensitivity, and reduce pharmacological toxicity [26, 27]. The milling process is conducted to make chitosan nanoparticles. This research shows that the particle size of chitosan nanoparticles is $247.3 \pm 38.1 \mu\text{m}$, which is expected to increase the effectiveness of antioxidative stress and antiapoptosis.

Oxidative stress and apoptosis often coexist in hyperglycemia and have been reported to have a role in multiorgan complications in diabetes mellitus. Overproduction of ROS leads to oxidative stress due to increased glucose autooxidation in hyperglycemia. Furthermore, ROS can trigger apoptosis signals, leading to cell damage [3, 4, 6, 11].

Streptozotocin-induced hyperglycemia in rats has been described as a useful experimental diabetes model for studying diabetic complications. Streptozotocin can interfere with the function of the beta cells of the islets of Langerhans, resulting in inhibition of insulin release, which in turn leads to hyperglycemia and diabetic complications like diabetic cardiomyopathy [6, 16]. The aim of the study was to evaluate the potency of antioxidative stress and antiapoptosis of chitosan nanoparticles to protect against streptozotocin-induced diabetic cardiomyopathy in rats.

The present study has revealed that when compared to the control group of rats, those injected with streptozotocin significantly exhibited elevated malondialdehyde and reduced endogenous antioxidant enzymes the SOD and GPx levels in cardiac tissue. Several investigators reported that the MDA level marker of lipid peroxidation was increased in hyperglycemia rats due to increased free radical




FIGURE 1: Chitosan nanoparticles in scanning electron microscope.




FIGURE 2: Size distribution of chitosan nanoparticles by dynamic light scattering.

TABLE 1: Effects of chitosan nanoparticle on in the level of MDA, SOD, and GPx of diabetic rat heart.

Group	MDA (nmol/mg tissue)	Means \pm standard deviation	
		SOD (U/mg tissue)	GPx (U/mg tissue)
Control group	58.9 ^a \pm 4.2	11.3 ^a \pm 1.01	1.56 ^a \pm 0.10
Streptozotocin group	82.4 ^b \pm 6.4	7.17 ^b \pm 0.83	0.94 ^b \pm 0.09
Chitosan nano 75 mg/kg BW	78.5 ^b \pm 4.3	8.42 ^b \pm 1.13	0.87 ^b \pm 0.13
Chitosan nano 150 mg/kg BW	72.8 ^b \pm 4.6	5.12 ^b \pm 0.81	0.91 ^b \pm 0.15
Chitosan nano 300 mg/kg BW	64.6 ^c \pm 3.7	7.17 ^c \pm 1.07	1.09 ^c \pm 0.09

^{a,b,c}Different superscript within each column indicate a significant difference between the mean ($p < 0.05$).

production. Streptozotocin increases the intensity of oxidative stress through autooxidation of monosaccharides leading to excessive production of superoxide and hydroxyl radicals, which can decrease the level of SOD and GPx. These radical species can oxidize polyunsaturated fatty acid membrane lipids to increase malondialdehyde, which results in necrosis in cardiac tissue [7, 20]. Various researchers have shown that streptozotocin can decrease the expression of the antioxidant responsive protein, Nrf2, thereby reducing the formation of antioxidants such as SOD and GPx [6, 15,

21]. In the diabetic rat, the oral administration of chitosan nanoparticles only at a dose of 300 mg/kg BW decreases MDA level and increases SOD and GPx levels significantly compared with the streptozotocin-induced diabetic cardiomyopathy. In recent years, chitosan has attracted much attention because of various biological activities related to its antioxidant activity and are utilized for studies in both in vivo and in vitro. This finding is supported by previous researchers who stated that chitosan has extreme antioxidant activity and can scavenge free radicals. The antioxidant




FIGURE 3: Western blot analysis of Nrf 2 protein expression of rat heart tissue. Nrf2 expression in rat heart control group (a); streptozotocin group (b); and chitosan nanoparticle group at dose 75 mg/kg BW (c), 150 mg/kg BW (d), and 300 mg/kg BW (e). ^{a-c}Columns that have different letters statistically differ ($p < 0.05$).

activity of chitosan as a free radical scavenger can be due to the OH group in the polysaccharide unit of chitosan that can react with hydroxyl free radicals (*OH) in the test of the hydroxyl radical assay. Also, the -NH_2 groups of the chitosan can form ammonium groups (NH_3^+) by absorbing H^+ ions and reacting with the OH radical through addition reaction to form stable macromolecules. As the intramolecular and intermolecular hydrogen bonds in chitosan molecules are solid (high bond dissociation energy), the OH and -NH_2 groups are difficult to separate and react with hydroxyl free radicals, in agreement with previous reports that the scavenging of ROS by chitosan may in part be related to increased activities of antioxidant enzymes and decreased levels of MDA. The cells possess an intricate network of defense mechanisms, including antioxidant compounds such as SOD and GPx, to neutralize excessive ROS accumulation [24, 27, 28]. In addition, Nrf2 is considered a master regulator of the antioxidant response, and various researchers have shown increased expression of Nrf2 by chitosan. The reason for this enhanced Nrf2 expression in the cardiac cells could be the chitosan-caused decreased intracellular ROS, which can increase antioxidant [28].

On the other hand, antiapoptosis has also been associated with cardiomyopathy in diabetic patients. This study showed that induction with streptozotocin could reduce the expression of Bcl-2, whereas the expression of caspase-3 increased in the heart of rats. Several researchers have proven that overproduction of ROS in oxidative stress could decrease expression of the antiapoptosis protein, Bcl-2, and increase expression of caspase-3, which lead to the fragmentation of DNA and apoptosis in the heart of rats after strep-

tozotocin administration [6, 7]. This could be due to the reduced expression of Nrf2 by streptozotocin. Nrf2 is considered a master regulator of the antioxidant response, and decreased expression of Nrf2 by streptozotocin has been shown by various researchers [19]. However, dose-dependent oral administration of chitosan nanoparticles could increase the expression of Bcl-2 and decrease the expression of caspase-3 in the heart of diabetic rats. This study demonstrated that chitosan nanoparticles with free radical scavenging ability to decrease ROS generation and enhance endogenous antioxidant activity such as SOD and GPx, leading to decreased oxidative stress and apoptosis that play an important role in the pathogenesis of various diabetes complications such as cardiomyopathy [29, 30]. The scavenging mechanism of chitosan is related to their hydrogen donating ability to free radicals to form stable molecules. Here, we clearly show that administration of chitosan nanoparticles on diabetic rats can reduce ROS formation and increase the level of antioxidant enzyme (SOD and GPx), resulting in an increase in Bcl-2 expression and a decrease caspase-3 expression, which has a vital role in cardiac cell apoptosis. Animal and human studies have found a correlation between hyperglycemia, ROS overproduction, and frequency of cardiac cell apoptosis. ROS inhibition with an antioxidant pretreatment reduced the intensity of oxidative stress and cardiac cell apoptosis [4, 6]. Recent studies have demonstrated that chitosan induced nuclear factor erythroid-derived2-like2 (Nrf2) activation. Nrf2, encoded by the gene NFE2L2, is a master regulator of phase II antioxidant enzyme that plays an essential role in the cellular protection against free radical damage and reduces the incidence of extremely derived degenerative diseases such as diabetic complications [31]. This result suggested that chitosan nanoparticles on diabetic rats can increase the level of antioxidant enzyme (SOD and GPx), resulting in an increase in Bcl-2 expression and a decrease in caspase-3 expression through Nrf2 activation.

In the results, we also showed that functional heart impairment in streptozotocin-induced diabetic cardiomyopathy was evidenced by the increased levels of biochemical markers such as CK-MB and LDH, which were significantly higher than the control group. The administration of chitosan nanoparticles at a dose of 300 mg/kg BW but not at a dose of 75 mg/kg BW and 150 mg/kg BW significantly reduced CK-MB and LDH levels in the heart cell damage of diabetic rats. Streptozotocin-induced cardiomyopathy is characterized by elevated serum CK-MB and LDH levels that are associated with increased ROS formation in oxidative stress. The ability of antioxidants to remove ROS has been demonstrated to play an important role in contributing to cardioprotective efficacy [5, 16]. The administration of chitosan nanoparticles significantly inhibits streptozotocin-induced heart cell damage, which is related to reduced CK-MB and LDH levels, suggesting that scavenger free radical of chitosan nanoparticles has the effect ability to inhibit heart cell damage caused by streptozotocin. These results agree with previous research that the antioxidant enzymes can interfere with streptozotocin-induced cardiomyopathy, as shown by decreased CK-MB and LDH levels. The reduced




FIGURE 4: Photomicrographs of immunohistochemical staining of Bcl-2 expression of rat heart tissue. (4A) Bcl-2 expression in rat heart (black arrow) from the control group (a); streptozotocin group (b); and chitosan nanoparticles group at a dose 75 mg/kg BW (c), 150 mg/kg BW (d), and 300 mg/kg BW; (4B) IOD/μm² shows Bcl-2 expression from semiquantitative evaluation (400×).




FIGURE 5: Photomicrograph of immunohistochemical staining of Caspase-3 expression of rat heart tissue. (A) Caspase-3 expression in rat heart (black arrow) from the control group (a); streptozotocin group (b); and chitosan nanoparticles group at dose 75 mg/kg Bw (c), 150 mg/kg/BW (d), and 300 mg/kg BW. B. IOD/μm² shows Caspase-3 expression from semiquantitative evaluation (400×).

release of CK-MB and LDH in the treatment groups demonstrated the protective effects of chitosan nanoparticles through antioxidants [24, 25].

In the present research, the histological investigation showed that the administration of streptozotocin caused necrosis in the cardiac cells. Recently, has been the realization that ROS-mediated peroxidation of membrane lipids and ROS-induced fragmentation of DNA is associated with necrosis and apoptosis [6, 17]. Therefore, inhibition of oxidative damage by supplementation of antioxidants becomes an attractive therapeutic strategy to reduce the risk of dia-

betic complications such as cardiomyopathy. The administration of the chitosan nanoparticles can protect against streptozotocin-induced heart damage. The histological observation clearly indicates that the administration of chitosan nanoparticles remarkably decreased necrosis in the cardiac cells induced by streptozotocin. This study shows that chitosan nanoparticles have cardioprotective activity through antioxidants and antiapoptosis. Therefore, it is hoped that chitosan nanoparticles can be used to help people with diabetes to prevent complications such as retinopathy, nephropathy, atherosclerosis, and cardiomyopathy.

TABLE 2: The effect of chitosan nanoparticle on the serum level of CK-MB and LDH of diabetic rat.

Group	Means \pm standard deviation	
	CK-MB (IU/L)	LDH (IU/L)
Control Group	70.4 ^a \pm 6.8	101.4 ^a \pm 8.4
Streptozotocin group	106.7 ^b \pm 8.6	152.6 ^b \pm 13.6
Chitosan nano 75 mg/kg BW	101.4 ^b \pm 6.9	147.3 ^b \pm 10.8
Chitosan nano 150 mg/kg BW	93.8 ^b \pm 7.1	139.7 ^b \pm 9.9
Chitosan nano 300 mg/kg BW	79.5 ^c \pm 5.7	124.5 ^c \pm 8.7

^{a,b,c}Different superscript within each column indicate a significant difference between the means ($p < 0.05$).




FIGURE 6: Histological study of administration of chitosan nanoparticle on streptozotocin-induced cardiac cell damage. The controls group showed normal morphology of the heart (a). The treatment streptozotocin group showed necrosis (indicated by black arrows) (b). Administration of chitosan nanoparticle 75 mg/kg BW and 150 mg/kg BW showed necrotic changes (c and d). However, administration of chitosan nanoparticle 300 mg/kg showed regeneration on cardiac cells damage (e) H and E, $\times 400$.

5. Conclusion

In conclusion, this study suggests that the administration of chitosan nanoparticles can protect cardiac cell damage in diabetic rats through antioxidative stress by decreasing ROS and increasing Nrf2 expression, level of SOD, and GPx and through antiapoptosis by increasing expression of Bcl-2 and decreasing expression of Caspase-3.

Data Availability

The data used to support the findings of this research are included within the article.

Conflicts of Interest

There are no conflicts of interest.

Acknowledgments

This research was supported by a grant from the Finance Ministry Educational Fund Management Institution (LPDP), the Republic of Indonesia, through Doctoral Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

References

- [1] O. M. Ighodaro, "Molecular pathways associated with oxidative stress in diabetes mellitus," *Biomedicine and Pharmacotherapy*, vol. 108, pp. 656–662, 2018.
- [2] U. Asmat, K. Abad, and K. Ismail, "Diabetes mellitus and oxidative stress—a concise review," *Saudi Pharmaceutical Journal*, vol. 24, no. 5, pp. 547–553, 2016.
- [3] C. M. O. Volpe, P. H. Villar-Delfino, P. M. F. dos Anjos, and J. A. Nogueira-Machado, "Cellular death, reactive oxygen species (ROS) and diabetic complications," *Cell Death Disease*, vol. 9, no. 2, pp. 119–131, 2018.

- [4] S. Sifuentes-Franco, D. E. Padilla-Tejeda, S. Carrillo-Ibarra, and A. G. Miranda-Díaz, "Oxidative stress, apoptosis, and mitochondrial function in diabetic nephropathy," *International Journal of Endocrinology*, vol. 2018, Article ID 1875870, 13 pages, 2018.
- [5] M. H. Abukhalil, O. Y. Althunibat, S. H. Aladaileh, A. I. Alfare, F. K. Al-Swailmi, and A. M. Mahmoud, "Galangin attenuates diabetic cardiomyopathy through modulating oxidative stress, inflammation and apoptosis in rats," *Biomedicine and Pharmacotherapy*, vol. 138, article 111410, 2021.
- [6] F. Shokri, M. Shokoohi, H. R. Niazkar, A. R. Abadi, H. Kalarestaghi, and M. Ahin, "Investigation the spermatogenesis and testis structure in diabetic rats after treatment with galega officinalis extract," *Crescent Journal of Medical and Biological Sciences*, vol. 6, no. 1, pp. 31–36, 2019.
- [7] M. A. Storz, "The role of vegan diets in lipotoxicity-induced beta-cell dysfunction in type-2-diabetes," *Journal of Population Therapeutics and Clinical Pharmacology*, vol. 27, pp. e22–e38, 2020.
- [8] A. M. T. Al Nahdi, A. John, and H. Raza, "Elucidation of molecular mechanisms of streptozotocin-induced oxidative stress, apoptosis, and mitochondrial dysfunction in Rin-5F pancreatic β -cells," *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 7054272, 15 pages, 2017.
- [9] A. R. Farrag, M. Nassar, and Z. El-Khayat, "Heteroxenia ghardaensis extract protects against DNA damage in streptozotocin-induced experimental diabetes," *Biomedical and Pharmacology Journal*, vol. 12, no. 1, pp. 71–78, 2019.
- [10] J. C. Jha, F. Ho, C. Dan, and K. Jandeleit-Dahm, "A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes," *Clinical Science*, vol. 132, 2018.
- [11] N. Matsumoto, D. Omagari, R. Ushikoshi-Nakayama, T. Yamazaki, H. Inoue, and I. Saito, "Hyperglycemia induces generation of reactive oxygen species and accelerates apoptotic cell death in salivary gland cells," *Pathobiology*, vol. 88, no. 3, pp. 234–241, 2021.
- [12] S. Kumar, S. Prasad, and S. L. Sitasawad, "Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats," *PLoS One*, vol. 8, no. 7, 2013.
- [13] S. A. Sudjarwo, K. Eraiko, G. W. Sudjarwo, and Koerniasari, "The potency of chitosan-Pinus merkusii extract nanoparticle as the antioxidant and anti-caspase 3 on lead acetate-induced nephrotoxicity in rat," *Journal of Advanced Pharmaceutical Technology & Research*, vol. 10, no. 1, pp. 27–32, 2019.
- [14] S. R. M. Sangdehi, A. H. Moghaddam, and M. Ranjbar, "Anti-apoptotic effect of silymarin-loaded chitosan nanoparticles on hippocampal caspase-3 and Bcl-2 expression following cerebral ischemia/reperfusion injury," *International Journal of Neuroscience*, vol. 21, pp. 1–8, 2021.
- [15] Z. Tang, P. Wang, C. Dong, J. Zhang, X. Wang, and H. Pei, "Oxidative stress signaling mediated pathogenesis of diabetic cardiomyopathy," *Oxidative Medicine and Cellular Longevity*, vol. 2022, Article ID 5913374, 8 pages, 2022.
- [16] L. Y. Yu, W. L. Shi, and G. X. Guo, "Cardio-protective role of gingerol along with prominent anti-diabetic cardiomyopathy action in a streptozotocin-induced diabetes mellitus rat model," *Cell Journal*, vol. 19, 2017.
- [17] M. Radenković, M. Stojanović, and M. Prostran, "Experimental diabetes induced by alloxan and streptozotocin: the current state of the art," *Journal of Pharmacological and Toxicological Methods*, vol. 78, pp. 13–31, 2016.
- [18] I. A. Bukhari, O. Y. Mohamed, and A. A. Almotrefi, "Cardio-protective effect of olive oil against ischemia reperfusion-induced cardiac arrhythmia in isolated diabetic rat heart," *Cureus*, vol. 12, 2020.
- [19] A. M. T. Al-Nahdi, A. John, and H. Raza, "Cytoprotective effects of N-acetylcysteine on streptozotocin-induced oxidative stress and apoptosis in RIN-5F pancreatic β -cells," *Cellular Physiology and Biochemistry*, vol. 51, no. 1, pp. 201–216, 2018.
- [20] M. Bigagli and M. Lodovici, "Circulating oxidative stress biomarkers in clinical studies on type 2 diabetes and its complications," *Oxidative Medicine of Cellular Longevity*, vol. 2019, article 5953685, 2019.
- [21] Y. Wanga, H. Sunb, J. Zhang, Z. Xia, and W. Chend, "Streptozotocin-induced diabetic cardiomyopathy in rats: ameliorative effect of piperine via Bcl 2, Bax/Bcl 2, and caspase-3 pathways," *Bioscience, Biotechnology, and Biochemistry*, vol. 84, 2020.
- [22] L. Ruixia Lan, C. Qingqing, W. Linlin, and Z. Zhihui, "The protect effects of chitosan oligosaccharides on intestinal integrity by regulating oxidative status and inflammation under oxidative stress," *Marine Drugs*, vol. 19, no. 2, 2021.
- [23] S. A. Sudjarwo, C. Anwar, G. Wardani, K. Eraiko, and Koerniasari, "Antioxidant and anti-caspase 3 effect of chitosan-Pinus merkusii extract nanoparticle against lead acetate-induced testicular toxicity in rat," *Asian Pacific Journal of Reproduction*, vol. 8, no. 1, pp. 13–19, 2019.
- [24] I. Aranaz, A. R. Alcántara, C. Civera et al., "Chitosan: An Overview of Its Properties and Applications," *Polymers*, vol. 13, pp. 3256–3286, 2021.
- [25] S. Kim, "Competitive biological activities of chitosan and its derivatives: antimicrobial, antioxidant, anticancer, and anti-inflammatory activities," *International Journal of Polymer Science*, vol. 2018, Article ID 1708172, 13 pages, 2018.
- [26] R. Saini, S. Saini, and S. Sharma, "Nanotechnology: the future medicine," *Journal of Cutaneous and Aesthetic Surgery*, vol. 3, no. 1, p. 32, 2010.
- [27] A. Kumari, V. Kumar, and S. K. Yadav, "Nanotechnology: a tool to enhance therapeutic values of natural plant products," *Research*, vol. 7, no. 2, pp. 34–42, 2012.
- [28] B. He, H. Tao, S. Liu, and A. Wei, "Protective effect of carboxymethylated chitosan on hydrogen peroxide-induced apoptosis in nucleus pulposus cells," *Molecular Medicine Reports*, vol. 11, no. 3, pp. 1629–1638, 2015.
- [29] I. M. Fang, C. H. Yang, C. M. Yang, and M. S. Chen, "Chitosan oligosaccharides attenuates oxidative-stress related retinal degeneration in rats," *PLoS One*, vol. 8, no. 10, 2013.
- [30] H. Saleh and H. M. El-Shorbagy, "Chitosan protects liver against ischemia-reperfusion injury via regulating Bcl-2/Bax, TNF- α and TGF- β expression," *International Journal of Biological Macromolecules*, vol. 164, pp. 1565–1574, 2020.
- [31] A. Chang-Bum, J. Jae-Young, K. Young-Sang, P. Sun-Joo, and I. K. Boo Il, "Induction of Nrf2-mediated phase II detoxifying/antioxidant enzymes in vitro by chitosan-caffeic acid against hydrogen peroxide-induced hepatotoxicity through JNK/ERK pathway," *Molecular and Cellular Biochemistry*, vol. 424, no. 1-2, pp. 79–86, 2017.